Risk determination of dyslipidemia in populations characterized by low levels of high-density lipoprotein cholesterol

American Heart Journal

Volumn 146, Issue 6, 2003, Pages 1052-1059

  Bersot, Thomas P ^a,b,c   Pépin, Guy M ^a   Mahley, Robert W ^a,b,c  

^a AMERICAN HOSPITAL   (Turkey)

^b GLADSTONE INSTITUTE OF CARDIOVASCULAR DISEASE   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ADULT; AGED; ARTICLE; DYSLIPIDEMIA; FEMALE; HIGH RISK POPULATION; HUMAN; LIFESTYLE; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; PRACTICE GUIDELINE; PRIMARY PREVENTION; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; TREATMENT INDICATION; TREATMENT PLANNING; TURKEY (REPUBLIC);

EID: 0344196953     PISSN: 00028703     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-8703(03)00516-7     Document Type: Article

References (62)

1. National Cholesterol Education Program Expert Panel. Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evoluotion, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001;285:2486-97.
2. Wood D, De Bocker G, Foergemon O, et al. Prevention of coronary heart disease in clinical practice: recommendations of the Second Joint Task Force of European ond Other Societies on Coronary Prevention: summary of recommendations. Eur Heart J 1998;19:1434-503.
3. Costelli WP, Gorrison RJ, Wilson PWF, et al. Incidence of coronory heart disease and lipoprotein cholesterol levels: the Framingham Study. JAMA 1986; 256:2835-8.
4. Assmonn G, Schulte H. Relation of high-density lipoprotein cholesterol ond triglycerides to incidence of atherosclerotic coronary artery diseose (the PROCAM experience). Am J Cardiol 1992;70:733-7.
5. Miller NE, Førde OH, Thelle DS, et al. The Tromsø Heart-Study. High-density lipoprotein ond coronary heart-diseose: a prospective case-control study. Lancet 1977;1:965-8.
6. Goldbourt U, Yoori S, Medolie JH. Isolated low HDL cholesterol as a risk factor for coronory heart disease mortality: a 21-year follow-up of 8000 men. Arterioscler Thromb Vasc Biol 1997;17:107-13.
7. Wilson PWF, D'Agostino RB, Levy D, et al. Prediction of coronory heart disease using risk factor categories. Circulation 1998;97:1837-47.
8. Grundy SM, Bolody GJ, Criqui MH, et al. Primary prevention of coronary heart diseose: guidance from Framingham: a statement for healthcare professionals from the AHA Task Force on Risk Reduction. Circulation 1998;97: 1876-87.
9. Genest JJ, McNomoro JR, Solem DN, et al. Prevalence of risk factors in men with premature coronory ortery disease. Am J Cardiol 1991;67:1185-9.
10. Rubins HB, Robins SJ, Collins D, et al. Distribution of lipids in 8,500 men with coronary artery disease. Am J Cardiol 1995;75:1196-201.
11. Downs JR, Cleorfield M, Weis S, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. JAMA 1998;279:1615-22.
12. Rubins HB, Robins SJ, Collins D, et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. N Engl J Med 1999;341:410-8.
13. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002;360:7-22.
14. Yusuf S. Two decades of progress in preventing vascular disease. Lancet 2002;360:2-3.
15. MRC/BHF Heart Protection Study Collaborative Group. Randomised trial of cholesterol-lowering therapy and of antioxidant vitamins in 20,536 people at increased risk of coronary heart disease death (Abstract). Circulation 2001; 104:2B-3B.
16. Sacks FM, Tonkin AM, Shepherd J, et al. Effect of pravastatin on coronary disease events in subgroups defined by coronary risk factors: the Prospective Pravastatin Pooling Project. Circulation 2000;102:1893-900.
17. Mahley RW, Palaoglu KE, Atak Z, et al. Turkish Heart Study: lipids, lipoproteins, and apolipoproteins. J Lipid Res 1995;36:839-59.
18. Onat A, Surdum-Avci G, Senocak M, et al. Plasma lipids and their interrelationship in Turkish adults. J Epidemiol Community Health 1992;46:470-6.
19. Onat A, Yildirim B, Uslu N, et al. Plasma lipoproteins and apolipoproteins in Turkish adults: overall levels, associations with other risk parameters and HDL's role as a marker of coronary risk in women (in Turkish). Arch Turk Soc Cardiol 1999;27:72-9.
20. Onat A, Keles I, Aksu H, et al. Prevalence of all-cause and coronary mortality in Turkish adults as assessed by 8-year follow-up data of the Turkish Adult Risk Factor Study (in Turkish). Arch Turk Soc Cardiol 1999;27:8-14.
21. Onat A, Senocak MS, Surdum-Avci G, et al. Prevalence of coronary heart disease in Turkish adults. Int J Cardiol 1993;93:23-31.
22. Onat A, Dursunoglu D, Sansoy V. Relatively high coronary death and event rates in Turkish women: relation to three major risk factors in five-year follow-up of cohort. Int J Cardiol 1997;61:69-77.
23. Onat A. Risk factors ond cardiovascular disease in Turkey. Atherosclerosis 2001;156:1-10.
24. Eckel RH, Krauss RM. American Heart Association call to action: obesity as a major risk factor for coronary heart disease. Circulation 1998;97:2099-100.
25. Brown CD, Higgins M, Donoto KA, et al. Body moss index and the prevalence of hypertension and dyslipidemia. Obes Res 2000;8:605-19.
26. Willett WC, Monson JE, Stampfer MJ, et al. Weight, weight change, and coronary heart disease in women: risk within the 'normal' weight range. JAMA 1995;273:461-5.
27. Jousilohti P, Tuomilehto J, Vortioinen E, et al. Body weight, cardiovascular risk foctors, and coronary mortality: 15-year follow-up of middle-aged men and women in eastern Finland. Circulation 1996;93:1372-9.
28. McGill HC Jr, McMohon CA, Herderick EE, et al. Obesity accelerates the progression of coronary atherosclerosis in young men. Circulation 2002;105: 2712-8.
29. Grundy SM. Obesity, metabolic syndrome, and coronary atherosclerosis. Circulation 2002;105:2696-8.
30. Gotto AM Jr, Whitney E, Stein EA, et al. Relation between baseline and on-treatment lipid parameters and first acute major coronary events in the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS). Circulation 2000;101:477-84.
31. Kinosion B, Glick H, Gorlond G. Cholesterol and coronary heart disease: predicting risks by levels and ratios. Ann Intern Med 1994;121:641-7.
32. Pedersen TR, Olsson AG, Færgemon O, et al. Lipoprotein changes and reduction in the incidence of major coronary heart disease events in the Scandinavian Simvastatin Survival Study (4S). Circulation 1998;97:1453-60.
33. Konnel WB, Wilson PWF. Efficacy of lipid profiles in prediction of coronary disease. Am Heart J 1992;124:768-74.
34. Grover SA, Palmer CS, Coupol L. Serum lipid screening to identify high-risk individuals for coronary death: the results of the Lipid Research Clinics Prevalence cohort. Arch Intern Med 1994;154:679-84.
35. Grover SA, Coupal L, Hu X-P. Identifying adults at increased risk of coronary disease: how well do the current cholesterol guidelines work? JAMA 1995; 274:801-6.
36. Stampfer MJ, Sacks FM, Salvini S, et al. A prospective study of cholesterol, apolipoproteins, and the risk of myocardial infarction. N Engl J Med 1991; 325:373-81.
37. Lemieux I, Lamarche B, Couillard C, et al. Total cholesterol/HDL cholesterol ratio vs LDL cholesterol/HDL cholesterol ratio as indices of ischemic heart disease risk in men: the Quebec Cardiovascular Study. Arch Intern Med 2001; 161:2685-92.
38. Ridker PM, Glynn RJ, Hennekens CH. C-reactive protein adds to the predictive value of total and HDL cholesterol in determining risk of first myocardial infarction. Circulation 1998;97:2007-11.
39. Ridker PM, Stampfer MJ, Rifoi N. Novel risk factors for systemic atherosclerosis: a comparison of C-reactive protein, fibrinogen, homocysteine, lipoprotein(a), and standard cholesterol screening as predictors of peripheral arterial disease. JAMA 2001;285:2481-5.
40. Ridker PM, Hennekens CH, Buring JE, et al. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med 2000;342:836-43.
41. Assmann G. Pro and con: high-density lipoprotein, triglycerides, and other lipid subfractions are the future of lipid management. Am J Cardiol 2001; 87(Suppl):2B-7B.
42. Mahley RW, Pépin GM, Bersot TP, et al. Turkish Heart Study update: plasma lipids and treatment guidelines for patients with low levels of high density lipoproteins (in Turkish). Arch Turk Soc Cardiol 2002;30:93-103.
43. Mahley RW, Pépin J, Palaoglu KE, et al. Low levels of high density lipoproteins in Turks, a population with elevated hepatic lipase: high density lipoprotein characterization and gender-specific effects of apolipoprotein E genotype. J Lipid Res 2000;41:1290-301.
44. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972;18:499-502.
45. Wong ND, Wilson PWF, Kannel WB. Serum cholesterol as a prognostic factor after myocardial infarction: the Framingham Study. Ann Intern Med 1991;115:687-93.
46. Pekkanen J, Linn S, Heiss G, et al. Ten-year mortality from cardiovascular disease in relation to cholesterol level among men with and without preexisting cardiovascular disease. N Engl J Med 1990;322:1700-7.
47. Frost PH, Verter J, Miller D. Serum lipids and lipoproteins after myocardial infarction: associations with cardiovascular mortality and experience in the Aspirin Myocardial Infarction Study. Am Heart J 1987;113:1356-64.
48. Ettinger WH, Wahl PW, Kuller LH, et al. Lipoprotein lipids in older people: results from the Cardiovascular Health Study. Circulation 1992;86:858-69.
49. Romm PA, Green CE, Reagan K, et al. Relation of serum lipoprotein cholesterol levels to presence and severity of angiographic coronary artery disease. Am J Cardiol 1991;67:479-83.
50. Frank CW, Weinblatt E, Shapiro S. Prognostic implications of serum cholesterol in coronary heart disease. In: Jones RJ, editor. Atherosclerosis. Proceedings of the Second International Symposium. New York: Springer-Verlag; 1970. p. 390-5.
51. Lavie CJ, Milani RV. National Cholesterol Education Program's recommendations, and implications of "missing" high-density lipoprotein cholesterol in cardiac rehabilitation programs. Am J Cardiol 1991;68:1087-8.
52. Rubins HB, Schectman G, Wilt TJ, et al. Distribution of lipid phenotypes in community-living men with coronary heart disease: high prevalence of isolated low, levels of high-density lipoprotein cholesterol. Arch Intern Med 1992;152:2412-6.
53. Kannel WB. Contributions of the Framingham Study to the conquest of coronary artery disease. Am J Cardiol 1988;62:1109-12.
54. Expert Panel. Summary of the second report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II). JAMA 1993; 269:3015-23.
55. Pearson TA, Laurora I, Chu H, et al. The Lipid Treatment Assessment Project (L-TAP): a multicenter survey to evaluate the percentages of dyslipidemic patients receiving lipid-lowering therapy and achieving low-density lipoprotein cholesterol goals. Arch Intern Med 2000;160:459-67.
56. Hoerger TJ, Bola MV, Bray JW, et al. Treatment patterns and distribution of low-density lipoprotein cholesterol levels in treatment-eligible United States adults. Am J Cardiol 1998;82:61-5.
57. Fonarow GC, French WJ, Parsons LS, et al. Use of lipid-lowering medications at discharge in patients with acute myocardial infarction: data from the National Registry of Myocardial Infarction 3. Circulation 2001;103:38-44.
58. Clearfield M, Whitney EJ, Weis S, et al. Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS): baseline characteristics and comparison with USA population. J Cardiovasc Risk 2000;7:125-33.
59. Gotto AM Jr, Boccuzzi SJ, Cook JR, et al. Effect of lovastatin on cardiovascular resource utilization and costs in the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS). Am J Cardiol 2000;86:1176-81.
60. Gotta AM Jr, Whitney E, Stein EA, et al. Application of the National Cholesterol Education Program and joint European treatment criteria and clinical benefit in the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS). Eur Heart J 2000;21:1627-33.
61. Tsevat J, Kuntz KM, Orav EJ, et al. Cost-effectiveness of pravastatin therapy for survivors of myocardial infarction with average cholesterol levels. Am Heart J 2001;141:727-34.
62. Johannesson M, Jönsson B, Kjekshus J, et al. Cost effectiveness of simvastatin treatment to lower cholesterol levels in patients with coronary heart disease. N Engl J Med 1997;336:332-6.